This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can Boston Scientific (BSX) Q4 Earnings Fuel Overall Growth?
by Zacks Equity Research
We are hopeful that Boston Scientific (BSX) will report a strong IC business globally in Q4, backed by an innovative portfolio and robust commercial teams.
Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q1 Earnings?
by Zacks Equity Research
On GW Pharmaceuticals' (GWPH) first-quarter fiscal 2019 conference call, investor focus will be on the initial sales uptake of its newly approved anti-epileptic drug, Epidiolex.
Can Zimmer Biomet (ZBH) Grow on Hip Business in Q4 Earnings?
by Zacks Equity Research
Within Hip business, we expect Zimmer Biomet (ZBH) to experience a strong uptick in the Asia-Pacific region.
Can CAG Growth Steadily Drive IDEXX (IDXX) in Q4 Earnings?
by Zacks Equity Research
IDEXX (IDXX) is expected to keep its momentum alive in Q4, banking on a strong global rise in Companion Animal Group Diagnostics' revenues.
MacroGenics Up on Lifting of Partial Hold on Cancer Candidate
by Zacks Equity Research
MacroGenics' (MGNX) shares rise as the FDA lifts partial clinical hold on its early-stage cancer candidate, MGD009, placed in December last year.
Will Overall Growth Aid Thermo Fisher's (TMO) Q4 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) rides high on a steadily strong analytical instrument business, flaunting robust global demand.
Can Solid Consumables Drive Illumina's (ILMN) Q4 Earnings?
by Zacks Equity Research
Illumina's (ILMN) management is optimistic about witnessing solid demand across the NovaSeq portfolio, which also includes the S2 and S1 flow cells.
What Lies Ahead for Abbott (ABT) Stock This Earnings Season?
by Zacks Equity Research
Abbott (ABT) is showing a steady rise on a healthy growth graph within its Diabetes Care business for a considerable period.
4 Medical Product Stocks Likely to Top Q4 Earnings Estimates
by Zacks Equity Research
Given the encouraging performance of the medical products industry for most part of 2018, it will be interesting see how the constituent companies perform in Q4.
Medical Products Industry Gathering Steam: 3 Stocks to Buy
by Nabaparna Bhattacharya
The Medical Products market is gaining traction from a firm exposure to robotics, medical mechatronics and the bipartisan two-year suspension of a 2.3% excise tax on MedTech manufacturers.
The Zacks Analyst Blog Highlights: Chimerix, MacroGenics, Rockwell Medical, TG Therapeutics and Valeritas
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chimerix, MacroGenics, Rockwell Medical, TG Therapeutics and Valeritas
5 Beaten-Down Medical Product Stocks to Rebound in 2019
by Nabaparna Bhattacharya
As the Medical product industry is witnessing temporary sluggishness, a sneak peek into some possible outperformers in 2019 could be a great idea for investors.
What's in Store for GW Pharma (GWPH) This Earnings Season?
by Zacks Equity Research
On GW Pharmaceuticals' (GWPH) fourth-quarter conference call, investor focus will be on the company's launch and commercialization plans for its newly approved anti-epileptic drug Epidiolex.
MacroGenics (MGNX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of 37.21% and 236.65%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
MacroGenics has been struggling lately, but the selling pressure may be coming to an end soon.
MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of 14.17% and 327.37%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Penumbra (PEN) This Earnings Season?
by Zacks Equity Research
Penumbra (PEN) deepens its focus on driving innovation, ramping up production and expanding geographies.
4 Medical Product Stocks Likely to Top Q3 Earnings Estimates
by Zacks Equity Research
The MedTech space received a sudden jolt when White House pulled the plug on Obamacare subsidies.